Publication:
Inborn Errors of Metabolism with Ataxia: Current and Future Treatment Options.

cris.virtual.author-orcid0000-0003-1358-1759
cris.virtualsource.author-orcid03091fff-b702-48f0-b01a-e5dbf07bc8c6
cris.virtualsource.author-orcida46d7de8-8aeb-4036-8cc2-06565b04a264
cris.virtualsource.author-orcid69416cd3-d6da-45a2-a1f0-0fa79402dd06
dc.contributor.authorBrémovà-Ertl, Tatiana
dc.contributor.authorHofmann, Jan
dc.contributor.authorStucki, Janine
dc.contributor.authorVossenkaul, Anja Maria
dc.contributor.authorGautschi, Matthias
dc.date.accessioned2024-10-25T18:13:28Z
dc.date.available2024-10-25T18:13:28Z
dc.date.issued2023-09-19
dc.description.abstractA number of hereditary ataxias are caused by inborn errors of metabolism (IEM), most of which are highly heterogeneous in their clinical presentation. Prompt diagnosis is important because disease-specific therapies may be available. In this review, we offer a comprehensive overview of metabolic ataxias summarized by disease, highlighting novel clinical trials and emerging therapies with a particular emphasis on first-in-human gene therapies. We present disease-specific treatments if they exist and review the current evidence for symptomatic treatments of these highly heterogeneous diseases (where cerebellar ataxia is part of their phenotype) that aim to improve the disease burden and enhance quality of life. In general, a multimodal and holistic approach to the treatment of cerebellar ataxia, irrespective of etiology, is necessary to offer the best medical care. Physical therapy and speech and occupational therapy are obligatory. Genetic counseling is essential for making informed decisions about family planning.
dc.description.numberOfPages44
dc.description.sponsorshipUniversitätsklinik für Kinderheilkunde
dc.description.sponsorshipUniversitätsklinik für Neurologie
dc.identifier.doi10.48350/186779
dc.identifier.pmid37759536
dc.identifier.publisherDOI10.3390/cells12182314
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/170337
dc.language.isoen
dc.publisherMDPI
dc.relation.ispartofCells
dc.relation.issn2073-4409
dc.relation.organizationDCD5A442BA49E17DE0405C82790C4DE2
dc.relation.organizationDCD5A442BADAE17DE0405C82790C4DE2
dc.relation.organizationDCD5A442BAE0E17DE0405C82790C4DE2
dc.relation.organizationDCD5A442C248E17DE0405C82790C4DE2
dc.subjectGM2-gangliosidosis Niemann-Pick type C abetalipoproteinemia acetyl-DL-leucine acetyl-L-leucine biomarkers cerebellar ataxia cerebrotendinous xanthomatosis disease-modifying treatment disorders of carbohydrate metabolism hereditary metabolic ataxia inborn error of metabolism lysosomal storage disorders metabolic diseases neurodegeneration neuroprotection ocular motor symptomatic treatment
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titleInborn Errors of Metabolism with Ataxia: Current and Future Treatment Options.
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.issue18
oaire.citation.volume12
oairecerif.author.affiliationUniversitätsklinik für Neurologie
oairecerif.author.affiliationUniversitätsklinik für Kinderheilkunde
oairecerif.author.affiliationUniversitätsklinik für Kinderheilkunde
oairecerif.author.affiliation2Universitätsinstitut für Klinische Chemie (UKC)
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2023-10-02 10:06:15
unibe.description.ispublishedpub
unibe.eprints.legacyId186779
unibe.refereedTRUE
unibe.subtype.articlereview

Files

Original bundle
Now showing 1 - 1 of 1
Name:
cells-12-02314.pdf
Size:
551.95 KB
Format:
Adobe Portable Document Format
File Type:
text
License:
https://creativecommons.org/licenses/by/4.0
Content:
published

Collections